Precigen Sees Unusually Large Options Volume (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) was the target of some unusual options trading activity on Thursday. Traders bought 11,343 call options on the company. This represents an increase of approximately 3,908% compared to the average volume of 283 call options.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Precigen in a report on Friday, November 15th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Iridian Asset Management LLC CT grew its holdings in shares of Precigen by 82.5% in the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after acquiring an additional 1,706,815 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after buying an additional 149,829 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Precigen by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock valued at $1,869,000 after buying an additional 130,500 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after buying an additional 127,467 shares during the last quarter. Finally, HighTower Advisors LLC increased its stake in shares of Precigen by 186.8% in the third quarter. HighTower Advisors LLC now owns 192,144 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 125,145 shares during the period. Institutional investors own 33.51% of the company’s stock.

Precigen Trading Up 3.6 %

NASDAQ PGEN traded up $0.04 during trading hours on Thursday, reaching $1.16. 3,514,395 shares of the company’s stock were exchanged, compared to its average volume of 1,008,707. The firm has a fifty day moving average of $0.84 and a 200-day moving average of $1.10. The stock has a market cap of $339.73 million, a PE ratio of -2.11 and a beta of 1.71. Precigen has a one year low of $0.65 and a one year high of $1.93.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.